Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor

Annals of Surgical Oncology

Volumn 21, Issue 7, 2014, Pages 2252-2258

  Mitteldorf, Christina ^a   Bertsch, Hans Peter ^b   Jung, Klaus ^c   Thoms, Kai Martin ^b   Schön, Michael Peter ^b   Tronnier, Michael ^a   Kretschmer, Lutz ^b  

^a Klinikum Hildesheim GmbH   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; OVERALL SURVIVAL; PT1 MELANOMA; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; TUMOR INVASION; ULCER; VERY ELDERLY; YOUNG ADULT; CANCER STAGING; FOLLOW UP; LYMPH NODE; LYMPH NODE METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84902212597     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3641-6     Document Type: Article

References (28)

1. Vermeeren L, van der Ent F, Sastrowijoto P, Hulsewé K. Sentinel lymph node biopsy in patients with thin melanoma: occurrence of nodal metastases and its prognostic value. Eur J Dermatol. 2010;20:30-34.
2. Zapas JL, Coley HC, Beam SL, Brown SD, Jablonski KA, Elias EG. The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy. J Am Coll Surg. 2003;197:403-7.
3. Kretschmer L, Preußer KP, Marsch WC, Neumann C. Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma. Melanoma Res. 2000;10:483-9.
4. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:1-10.
5. Ranieri JM, Jeffrey DM, Wenck S, Johnson CS, Coleman JJ. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13:927-32.
6. Sekula-Gibbs SA, Shearer MA. Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one. Dermatol Surg. 2011;37:1080-88.
7. Yonick DV, Ballo RM, Kahn E, et al. Predictors of positive sentinel lymph node in thin melanoma. Am J Surg. 2011;201:324-8.
8. Cecchi R, Buralli L, Innocenti S, De Gaudio C. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol. 2007;34:512-5.
9. Kretschmer L, Starz H, Thoms KM, et al. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J Cancer. 2011;129:1435-42.
10. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48.
11. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw. 2009;7:308-17.
12. Socrier Y, Lauwers-Cances V, Lamant L, et al. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. Br J Dermatol. 2010;162:830-34.
13. Olah J, Gyulai R, Korom I, et al. Tumor regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol. 2003;149:662-3.
14. Murali R, Haydu LE, Quinn M, et al. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg. 2012;255:128-33.
15. Lefevre M, Vergier B, Balme B, et al. Relevance of vertical growth pattern in thin level II cutaneous superficial spreading melanomas. Am J Surg Pathol. 2003;27:717-24.
16. Mitteldorf C, Bertsch HP, Zapf A, Neumann C, Kretschmer L. Cutting a sentinel lymph node into slices is the optimal first step for examination of sentinel lymph nodes in melanoma patients. Mod Pathol. 2009;22:1622-7.
17. Starz H, Balda BR, Krämer KU, Büchels H, Wang H A. Micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer. 2001;91:2110-21.
18. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-34.
19. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008;143:892-99; discussion 899-900.
20. Bleicher RJ, Essner R, Foshag J, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanoma. J Clin Oncol. 2003;21:1326-31.
21. Mozzilla N, Pennacchioli E, Gandimi S, et al. Sentinel node biopsy in thin and thick melanoma. Ann Surg Oncol. 2013;20:2780-86.
22. Murali R, Hughes MT, Fitzgerald P, Thompson JF, Scolyer RA. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly Clark level, affects pathologic staging of primary cutaneous melanoma. Ann Surg. 2009;249:641-7.
23. Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571-6.
24. Bagaria SP, Ray PS, Joseph RW, et al. Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma. Cancer. 2013;119:1860-67.
25. Requena C, Botella-Estrada R, Traves V, Nagore E, Almenar S, Guillén C. Problems in defining melanoma regression and prognostic implication. Actas Dermosifiliogr. 2009;100:759-66.
26. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res. 2003;36:347-50.
27. Rousseau DL Jr, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003;10:569-74.
28. Ostmeier H, Fuchs B, Otto F, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer. 1999;85:2391-9.